
For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers.
from CBC | Health News https://ift.tt/2HCiVMM
Aucun commentaire:
Enregistrer un commentaire